Public Release: 

Preventing gastric cancer with antibiotics

Faculty of 1000

Helicobacter pylori, a bacterium found in about 50% of humans worldwide, can cause stomach ulcers and, in extreme cases, gastric cancer. In an article for F1000 Medicine Reports, Seiji Shiota and Yoshio Yamaoka discuss the possible eradication of H. pylori infections

Infection by the H. pylori bacterium can approach 100% in developing countries. Most infected people do not have symptoms, but many develop problems including stomach ulcers. H. pylori causes more than 90% of all duodenal ulcers and can also contribute to the development of gastric cancer, which is one of the world's biggest medical problems.

Shiota and Yamaoka, from Oita University, Japan, and Baylor College of Medicine, Texas, respectively, report on a large multicenter trial in Japan. Patients with early gastric cancer were randomly treated with H. pylori antibiotics after surgical resection and were followed up for three years. Patients who received antibiotic treatment had a significantly lower risk of developing gastric cancer, confirming the importance of careful management of H. pylori.

However, certain populations (e.g. India and Thailand) have a high prevalence of H. pylori infection but a low incidence of gastric cancer. It is thought that certain strains of H. pylori (especially east-Asian cytotoxin-associated gene [cagA]-positive strains) might carry an increased risk of developing gastric cancer, but currently identified cagA genotypes in the Asia-Pacific are not associated with cancer.

Shiota and Yamaoka write, "bacterial virulence factors, host genetic factors, and environmental factors contribute to the risk for developing gastric cancer, and further studies are necessary."

But they warn that practitioners need to exercise caution with regard to widespread antibiotic treatment, saying, "if all infected persons are to be treated, we should consider the increase in frequency of antibiotic resistance and unexpected consequences such as esophageal adenocarcinoma, asthma, and autoimmune disease."

###

Notes to Editors

1. Yoshio Yamaoka, Faculty Member for Faculty of 1000 Medicine, is Director of the Molecular Pathogenesis Laboratory, Michael E DeBakey VA Medical Center, United States of America http://f1000medicine.com/member/5087527452029620

2. Seiji Shiota is a medical researcher at Oita University Faculty of Medicine, Oita, Japan.

3. The full text of the article is available at available for reporters at: http://faculty1000.files.wordpress.com/2010/03/yamaoka.pdf or for subscribers at http://f1000.com/reports/medicine/content/2/20

4. Please name F1000 Medicine Reports and Faculty of 1000 Medicine in any story you write. If you are writing for the web, please link to the website (details below).

5. The F1000 Medicine Reports journal (ISSN 1757-5931), publishes short commentaries by expert clinicians focussing on the most important studies identified by Faculty of 1000 Medicine that are likely to change clinical practice. The commentaries summarise the implications of important new research findings for clinicians http://f1000medicine.com/reports

6. Faculty of 1000, http://f1000.com, is a unique online service that helps scientists and clinicians stay informed. Our distinguished international faculty of over 5000 top-ranked researchers elect, evaluate and provide opinion on key articles across the life sciences, bringing you a rapidly updated, authoritative guide to the literature that matters.

Media Contact
Steve Pogonowski
PR Manager
Faculty of 1000
press@f1000.com

http://blog.f1000.com
http://twitter.com/f1000
http://youtube.com/Facultyof1000

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.